Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
| Name (Synonyms) | Correlation | |
|---|---|---|
| drug3182 | Quantitative IgG Test Wiki | 1.00 |
| drug1181 | Delayed diagnostics Anyplex TMII RV16 Detection Wiki | 1.00 |
| drug3271 | Rapid diagnostics using Anyplex TMII RV16 Detection Wiki | 1.00 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| D005335 | Fever of Unknown Origin NIH | 1.00 |
| D002637 | Chest Pain NIH | 1.00 |
| D004417 | Dyspnea NIH | 0.30 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| HP:0100749 | Chest pain HPO | 1.00 |
| HP:0002098 | Respiratory distress HPO | 0.30 |
Navigate: Correlations HPO
There is one clinical trial.
Richmond Research Institute (RRI) is applying existing and new COVID-19 PCR and antibody tests to help develop methodologies which provide fast and accurate results. Infection with coronavirus (SARS-CoV-2) is currently a worldwide pandemic and reliable testing for COVID-19 is crucial to understand who is infected and therefore a risk to others by spreading the infection. The tests that are currently being investigated by RRI include: A. The RAPG-COV-019 kit, a small testing cartridge developed by Biopanda Reagents which detects whether an individual has been infected by the coronavirus (SARS-CoV-2) by using a spot of the person's blood and displays these results in 10 minutes. B. An already established laboratory test that detects SARS-CoV-2 by a process known as polymerase chain reaction (PCR). This test is accurate but expensive, time consuming and requires highly trained staff and laboratory facilities. C. Development of a quantitative laboratory reference test for antibodies (IgG) against the novel SARS-CoV-2 virus. The above tests are being used by RRI to follow infections (PCR) and immunity (IgG) in their workforce, as well as their families and visitors to their site. The RAPG-COV-019 kit can be used by non-experts and provides results within minutes, and would allow rapid, inexpensive diagnosis of coronavirus (SARS-CoV-2) infection. The results will enable determination of whether the RAPG-COV-019 kit can make a reliable diagnosis. Collecting this data also allows the gathering of epidemiological data on SARS-CoV-2 including incidence, prevalence and information on asymptomatic carriers. Furthermore, identifying individuals that are infected with SARS-CoV-2 has great potential to improve health outcomes by allowing infected individuals to seek the correct medical treatment as well as self-isolate and reduce transmission.
Description: Identification of trial participants who are asymptomatic carriers of SARS-CoV-2 by comparing the results of a blood finger stick test and reference laboratory tests to PCR testing for acute infection
Measure: Identification of asymptomatic carriers of SARS-CoV-2 Time: Through study completion, estimated 12 weeksDescription: Validation the sensitivity, specificity and reproducibility of the RAPG-COV-019 kit to detect SARS-CoV-2 infection. To help develop a quantitative laboratory reference test for antibodies (IgG) to gain an understanding of quantity of antibodies that people develop and how these decrease over time.
Measure: Validation of the ability of the immunoassay kit to detect antibodies to SARS-CoV-2 Time: Through study completion, estimated 12 weeksDescription: Determination of the understanding of the quantity of IgG antibodies developed as a response to SARS-CoV-2 infection, and how these antibody levels decrease over time. Antibody titres will be measured in infected individuals, over multiple days and correlated with disease parameters. This will facilitate the development of a quantitative laboratory reference test for IgG antibodies
Measure: Development of a quantitative laboratory reference test for the measurement of SARS-CoV-2 Time: Through study completion, estimated 12 weeksDescription: Execution of an epidemiological study on SARS-CoV-2 carriage and transmission in a well-controlled clinical environment with extensive measures in place to prevent viral transmission
Measure: Exploration of SARS-CoV-2 epidemiology Time: Through study completion, estimated 12 weeksAlphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports